Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2010

01-05-2010 | Translational Research and Biomarkers

p21 Waf1/Cip1 Polymorphisms and Risk of Esophageal Cancer

Authors: Wenjun Yang, PhD, Qi Qi, MD, Heng Zhang, MD, Wenda Xu, MD, Zhiqiang Chen, MD, Li Wang, Yin Wang, PhD, Xiaowei Dong, Haiyan Jiao, MD, Zhenghao Huo, MD

Published in: Annals of Surgical Oncology | Issue 5/2010

Login to get access

Abstract

Background

As the main downstream effecter of tumor suppressor p53, p21Waf1/Cip1 functions as a unique link from p53 to cell-cycle arrest and DNA repair. In contrast to p53, p21Waf1/Cip1 has general rare mutations. The natural genetic variants of p21Waf1/Cip1 have thus emerged for study to enhance understanding of interindividual differences in cancer risk. Two polymorphisms in the p21 Waf1/Cip1 gene, i.e., codon 31 in the coding region and IVS2+16 in intron 2, have been identified and appeared to influence the expression of p21Waf1/Cip1. The aim of this study is to investigate the potential association of the above two variants, including one new single-nucleotide polymorphism (SNP) 309 in the promoter region of p21 Waf1/Cip1 , with susceptibility to esophageal cancer (EC).

Patients and Methods

The study involved 80 cancer patients and 200 cancer-free controls from Ningxia Region of China. Three variations (codon 31, IVS2+16, and SNP 309) were identified by polymerase chain reaction (PCR) direct sequencing method, and associations of each individual SNP and haplotypes of the three SNPs with esophageal cancer were analyzed.

Results

The correlation results supported that codon 31 Ser homozygosity conferred risk for the process of developing EC [odds ratio (OR) = 2.542, 95% confidence interval (CI) = 1.347–4.730]. In the combined study of the three variations, HapA and HapB appeared to influence the risk of EC.

Conclusions

Our findings indicated that codon 31 Ser allele homozygosity, either alone or in combination with the other two SNPs, may be associated with development of EC. These findings warrant validation in a larger study of EC patients.
Literature
1.
He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):124–34.CrossRefPubMed
2.
Kuwano H, Kato H, Miyazaki T, et al. Genetic alterations in esophageal cancer. Surg Today. 2005;35(1):7–18.CrossRefPubMed
3.
4.
Cao B, Tian X, Li Y, et al. LMP7/TAP2 gene polymorphisms and HPV infection in esophageal carcinoma patients from a high incidence area in China. Carcinogenesis. 2005;26:1280–4.CrossRefPubMed
5.
Cheung WY, Geoffrey L. Genetic variations in esophageal cancer risk and prognosis. Gastroenterol Clin North Am. 2009;38(1):75–91.CrossRefPubMed
6.
El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75(4):817–25.CrossRefPubMed
7.
Rati F, Mourad B, Arun F. Role of p21WAF1 in the cellular response to UV. Cell Cycle. 2004;3(2):134–7.
8.
Shiohara M, el-Deiry WS, Wada M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood. 1994;84(11):3781–4.PubMed
9.
Sun Y, Hildesheim A, Li H, et al. No point mutation but a codon 31ser>arg polymorphism of the WAF-1/CIP-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol Biomarkers Prev. 1995;4:261–7.PubMed
10.
Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene. 2006;25:602–1611.CrossRef
11.
Law JC, Deka A. Identification of a PstI polymorphism in the p21WAF1/Cip1 cyclin-dependent kinase inhibitor gene. Hum Genet. 1995;95(4):459–60.CrossRefPubMed
12.
Xi YG, Ding KY, Su XL, et al. p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis. 2004;11:2201–6.CrossRef
13.
Choi YY, Kang HK, Choi JE, et al. Comprehensive assessment of P21 polymorphisms and lung cancer risk. J Hum Genet. 2008;53:87–95.CrossRefPubMed
14.
Stephens M, Smith N, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978–89.CrossRefPubMed
15.
Shen ZY, Hu SP, Lu LC, et al. Detection of Human Papillomavirus in Esophageal Carcinoma. J Med Virol. 2002;68:412–6.CrossRefPubMed
16.
Datian B, Ming HT, Yen LL, et al. Association of p53 and 21(CDKN1A/WAF1/CIP1) polymorphisms with oral cancer in Taiwan patients. Anticancer Res. 2007;27:1559–64.
17.
Bahl R, Arora S, Nath N, et al. Novel polymorphism in p21(waf1/cip1) cyclin dependent kinase inhibitor gene: association with human esophageal cancer. Oncogene. 2000;19(3):323–8.CrossRefPubMed
18.
Xi YG, Ding KY, Ren YH, et al. Esophageal cancer in Chinese population : no polymorphism in codon 149 of p21 WAF1/CIP1 cyclin dependent kinase gene. Oncogene. 2002;21:7745–8.CrossRefPubMed
19.
Su L, Sai Y, Fan R, et al. p53 (codon 72) and p21 (codon 31) polymorphisms after in vivo mRNA expression of p21. Mol Carcinog. 1996;16(4):221–8.CrossRef
20.
Roh J, Kim M, Kim J, et al. Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. Cancer Lett. 2001;165(1):59–62.CrossRefPubMed
21.
Roh JW, Kim JW, Park NH, et al. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol. 2004;93(2):499–505.CrossRefPubMed
22.
Wu MT, Wu DC, Hsu HK, et al. Association between p21 codon 31 polymorphism and esophageal cancer risk in a Taiwanese population. Cancer Lett. 2003;201(2):175–80.CrossRefPubMed
23.
Popanda O, Edler L, Waas P, et al. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer. 2007;55(1):25–34.CrossRefPubMed
24.
Tsai MH, Chen WC, Tsai FJ, et al. Correlation of p21 gene codon 31 polymorphism and TNF-alpha gene polymorphism with nasopharyngeal carcinoma. J Clin Lab Anal. 2002;16(3):146–50.CrossRefPubMed
Metadata
Title
p21 Waf1/Cip1 Polymorphisms and Risk of Esophageal Cancer
Authors
Wenjun Yang, PhD
Qi Qi, MD
Heng Zhang, MD
Wenda Xu, MD
Zhiqiang Chen, MD
Li Wang
Yin Wang, PhD
Xiaowei Dong
Haiyan Jiao, MD
Zhenghao Huo, MD
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 5/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0882-x

Other articles of this Issue 5/2010

Annals of Surgical Oncology 5/2010 Go to the issue

Gastrointestinal Oncology

Critical Assessment of Risk Factors for Complications After Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei

EMERGING THERAPEUTIC APPROACHES TO HEPATOCELLULAR CARCINOMA

Surgical Resection of High-Risk Hepatocellular Carcinoma: Patient Selection, Preoperative Considerations, and Operative Technique

Urologic Oncology

The Diminishing Role of Transurethral Resection of the Prostate

Gastrointestinal Oncology

Tumorigenic Role of Podoplanin in Esophageal Squamous-Cell Carcinoma

Gastrointestinal Oncology

New Metastatic Lymph Node Ratio System Reduces Stage Migration in Patients Undergoing D1 Lymphadenectomy for Gastric Adenocarcinoma

Colorectal Cancer

Anterior Perineal PlanE for Ultralow Anterior Resection of the Rectum (The APPEAR Technique): A Video Demonstration